Senti Biosciences Holdings, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
0.3770
-0.0005 (-0.13%)
At close: Aug 28, 2026, 4:00 PM EDT
0.3946
+0.0176 (4.67%)
After-hours: Aug 28, 2026, 7:59 PM EDT
SNTI Revenue
Senti Biosciences Holdings had revenue of $17.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $55.00K. In the year 2025, Senti Biosciences Holdings had annual revenue of $22.00K.
Revenue (ttm)
$55.00K
Revenue Growth
n/a
P/S Ratio
213.48
Revenue / Employee
$1,410
Employees
39
Market Cap
11.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
| Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
| Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vistagen Therapeutics | 2.50M |
| Daré Bioscience | 1.37M |
| CytoMed Therapeutics | 669.28K |
| Aspire Biopharma Holdings | 97.66K |
| Kiora Pharmaceuticals | 20.00K |
SNTI News
- 10 days ago - Senti Biosciences Holdings Proxy statement: Proxy filing - Filings
- 16 days ago - Senti Biosciences Holdings Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Senti Biosciences Holdings Proxy statement: Proxy filing - Filings
- 6 weeks ago - Senti Biosciences Holdings Registration statement: Registration filing - Filings
- 6 weeks ago - Senti Bio announces transaction to spin off Gene-Circuit-enabled pipeline - TheFly
- 6 weeks ago - Senti Biosciences Holdings Proxy statement: Proxy filing - Filings
- 6 weeks ago - Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform - GlobeNewsWire
- 2 months ago - Senti Biosciences Holdings Registration statement: Registration filing - Filings